In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.

  title={In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia.},
  author={Thomas J. Raedler and Michael B. Knable and Douglas W. Jones and Richard A Urbina and Julia G. Gorey and Kan Sam Lee and Michael Egan and Richard Coppola and Daniel R. Weinberger},
  journal={The American journal of psychiatry},
  volume={160 1},
OBJECTIVE Postmortem studies have implicated the central muscarinic acetylcholine system in schizophrenia. However, central muscarinic receptor availability has not previously been studied in vivo. Using [I-123]iodoquinuclidinyl benzilate ([(123)I]IQNB) single photon emission computed tomography (SPECT), the authors sought to compare the muscarinic receptor availability in vivo in unmedicated patients with schizophrenia and normal subjects. METHOD Twelve medication-free patients with… 

Figures and Tables from this paper

Central Muscarinic Acetylcholine Receptor Availability in Patients Treated with Clozapine

Preliminary data indicate that reduction of mus carinic receptor availability by clozapine can be measured in vivo and that moderate daily doses are associated with moderate to high reductions of muscarinic receptors availability.

Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia

Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia.

The data suggest that a marked decrease in [(3)H]pirenzepine binding in BA 9 from a subset of people with schizophrenia is predictive of decreases in muscarinic receptors in other central nervous system (CNS) regions, however, there were some region-specific decreases.

Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia

In a subgroup of participants with schizophrenia, there is a widespread decreased responsiveness to a positive allosteric modulator at the CHRM1.

Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia

Being able to define a subgroup within schizophrenia using a central biological parameter is a pivotal step towards understanding the biochemistry underlying at least one form of the disorder and may represent a biomarker that can be used in neuroimaging.

Muscarinic mechanisms in psychotic disorders.

It is proposed that an agonist with M(1) and M(4) interactions would effectively treat core symptom clusters associated with schizophrenia.



The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography.

The data suggest that focal abnormalities in muscarinic binding in vivo may characterize some patients with Alzheimer's disease and Pick's disease, but further studies are needed to address questions about partial volume artifacts and receptor quantification.

D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

The hypothesis of generally elevated central D2 dopamine receptor densities in schizophrenia was not supported by the present findings, and significantly higher densities were found in the left than in the right putamen but not in the caudate nucleus.

Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.

Schizophrenia itself is associated with an increase in brain D2 dopamine receptor density, and the densities in the caudate nucleus were higher in both groups of patients than in the normal volunteers.

The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia.

The density of M1 receptors was decreased in the caudate-putamen from the schizophrenic subjects and this data raise the possibility that changes in muscarinic receptors may be involved in the pathology of schizophrenia.

Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia

Worsening of negative symptoms may be associated with increased availability of striatal D2 receptors, perhaps because of decreased concentrations of endogenous dopamine.

Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography.

Average striatal dopamine transporter density is unaltered in neuroleptic-naive patients with schizophrenia, however, patients lack asymmetry in caudate dopamine transporter binding, which conforms with disrupted brain lateralization in this disorder.